Daxor Corporation announced new data demonstrating the importance and clinical utility of Daxor's BVA-100 blood test in heart failure (HF) patients published in the Journal of Cardiac Failure. The results of the study show that Daxor's BVA-100® provides unique and actionable data that is critical for addressing heart failure in patients. The Journal of Cardiac Failureis the official peer reviewed journal of the Heart Failure Society of America and the Japanese Heart Failure Society.

The study titled, “Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure,” sought to test the relationship (or lack thereof) between a commercially available implantable pulmonary artery pressure (PAP) monitor, estimates of cardiac blood volume, and actual circulating blood volume as determined by Daxor's technology. The results showed that there is a lack of agreement between PAP and blood volume metrics, confirming that the two variables should be thought of as independent variables for physicians to target.